Core Insights - Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases [3] - The company will participate in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025 [1] Company Overview - Cartesian Therapeutics is pioneering mRNA CAR-T therapies, with its lead asset Descartes-08 entering Phase 3 clinical development for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus [3] - Descartes-08 has received FDA agreement under the Special Protocol Assessment for its Phase 3 trial [3] - The company also has Descartes-15, an autologous anti-BCMA mRNA CAR-T in Phase 1 trial for multiple myeloma [3] Event Information - A live webcast of the conference presentation will be available on the company's website, along with an archived replay for a limited time [2]
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference